Compare Amylx Pharmaceuticals Inc (AMLX) vs Charter Communications Inc (CHTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Charter Communications Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Charter Communications Inc trades at $157.69 (market cap $18.28B). The key difference: Charter Communications Inc is far larger — about 7.2× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Charter Communications Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | CHTR | |
|---|---|---|
Market Cap | $2.53B | $18.28B |
Sector | Health | Media |
52-Week High | $24.19 | $282.74 |
52-Week Low | $7.82 | $123.31 |
Enterprise Value | $2.28B | $114.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
Charter Communications (CHTR) trades at $152.57, down 3.09% on the day, with a bullish technical signal from moving averages but mixed oscillators. The stock shows low valuation multiples with a P/E of 3.97 and P/S of 0.36, supported by a 9.05% net income margin and strong operating cash flow of $16.08B in 2025. Recent Q2 2026 earnings beat expectations with EPS of $10.66 versus $9.98 estimated, though revenue declined 1.7% year-over-year. News highlights debt refinancing activities and competitive pressures in broadband.
The outlook remains cautious due to subscriber losses and fiber competition, but the extreme valuation discount and aggressive buybacks offer potential upside. Risks include high debt leverage at $93.21B long-term and persistent industry headwinds. Analyst consensus is mixed with a $166.18 price target, suggesting 9% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Charter Communications Inc
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →
